These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937 [TBL] [Abstract][Full Text] [Related]
9. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698 [TBL] [Abstract][Full Text] [Related]
10. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer. Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840 [TBL] [Abstract][Full Text] [Related]
11. Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. Cook BE; Adumeau P; Membreno R; Carnazza KE; Brand C; Reiner T; Agnew BJ; Lewis JS; Zeglis BM Bioconjug Chem; 2016 Aug; 27(8):1789-95. PubMed ID: 27356886 [TBL] [Abstract][Full Text] [Related]
13. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET. Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836 [TBL] [Abstract][Full Text] [Related]
14. HER2-targeted antibody drug conjugates for ovarian cancer therapy. Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865 [TBL] [Abstract][Full Text] [Related]
15. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277 [TBL] [Abstract][Full Text] [Related]
16. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation. Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899 [TBL] [Abstract][Full Text] [Related]
17. Imaging and Monitoring HER2 Expression in Tumors during HER2 Antibody-Drug Conjugate Therapy Utilizing a Radiolabeled Site-Specific Single-Domain Antibody Probe: Ge S; Wang C; You X; He H; Zhang B; Jia T; Cai X; Sang S; Xu T; Deng S J Med Chem; 2024 Aug; 67(15):12855-12867. PubMed ID: 39077778 [TBL] [Abstract][Full Text] [Related]
18. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944 [TBL] [Abstract][Full Text] [Related]
19. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability. Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J MAbs; 2021; 13(1):1914885. PubMed ID: 33904380 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]